Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 20;9(1):e70100.
doi: 10.1002/jgh3.70100. eCollection 2025 Jan.

Comparative Study of Remimazolam and Midazolam During Sedated Upper Gastrointestinal Endoscopy: A Propensity Score Matching Analysis

Affiliations

Comparative Study of Remimazolam and Midazolam During Sedated Upper Gastrointestinal Endoscopy: A Propensity Score Matching Analysis

Ryoji Ichijima et al. JGH Open. .

Abstract

Aim: This study aimed to compare the use of remimazolam and midazolam in upper gastrointestinal endoscopy in Japan as a sub-analysis of data from an investigator-initiated clinical trial of remimazolam.

Methods and results: Patients in two groups were matched using propensity score matching. We evaluated the time from the end of the gastrointestinal endoscopy until discharge, the time from the end of the procedure until awakening, and adverse events. Overall, 36 participants from the clinical trial population who underwent upper gastrointestinal endoscopy using remimazolam and 199 patients who underwent the procedure with midazolam during the same period were included in this study. Following propensity score matching, 34 patients in both groups were matched. The median time from the end of the procedure until awakening was 27.0 min (23.0-40.5 min) in the midazolam group (Group M) and 0 min (0-5.0 min) in the remimazolam group (Group R); the median time from the end of the upper gastrointestinal endoscopy until discharge was 39.0 min (35.0-52.5 min) in Group M and 5.0 min (0-5.0 min) in Group R (p < 0.01). Reported adverse events were hypotension and hypoxemia in one patient in Group R.

Conclusion: Compared with midazolam, remimazolam significantly shortened the time to patient awakening and duration until the patient could leave the endoscopy room. Trial Registration: The main study (REM-IICT JP1) is registered with the Japan Registry of Clinical Trails: jRCT2031200360.

Keywords: endoscopy; gastrointestinal; midazolam; propensity score; remimazolam.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Study flow chart. EGD, upper gastrointestinal endoscopy; M group, midazolam group; R group, remimazolam group.

Similar articles

References

    1. Siegel R., Naishadham D., and Jemal A., “Cancer Statistics, 2012,” CA: A Cancer Journal for Clinicians 62 (2012): 10–29. - PubMed
    1. Park C. H., Park S. W., Jung J. H., et al., “Clinical Outcomes of Sedation During Emergency Endoscopic Band Ligation for Variceal Bleeding: Multicenter Cohort Study,” Digestive Endoscopy 32 (2020): 894–903. - PubMed
    1. Wang D., Chen C., Chen J., et al., “The Use of Propofol as a Sedative Agent in Gastrointestinal Endoscopy: A Meta‐Analysis,” PLoS One 8 (2013): e53311. - PMC - PubMed
    1. McQuaid K. R. and Laine L., “A Systematic Review and Meta‐Analysis of Randomized, Controlled Trials of Moderate Sedation for Routine Endoscopic Procedures,” Gastrointestinal Endoscopy 67 (2008): 910–923. - PubMed
    1. Benson A. A., Cohen L. B., Waye J. D., Akhavan A., and Aisenberg J., “Endoscopic Sedation in Developing and Developed Countries,” Gut and Liver 2 (2008): 105–112. - PMC - PubMed

LinkOut - more resources